Reuters logo
BRIEF-Heat Biologics presents immune data on bladder cancer drug
2017年2月17日 / 中午12点25分 / 9 个月前

BRIEF-Heat Biologics presents immune data on bladder cancer drug

Feb 17 (Reuters) - Heat Biologics Inc-

* Researchers reported that hs-410, in combination with bcg, continues to be generally well-tolerated

* Researchers reported hs-410 activates cd8+ t cells and these immune responders appear to have lower recurrence rate than non-immune responders

* Patients were evaluated based on their levels of tumor infiltrating lymphocytes (til) at start of treatment in phase 2 trial

* In placebo arm, patients with low til levels at baseline had higher incidence of disease recurrence than patients with high til levels at baseline

* In vaccine-treated group, recurrence levels were essentially same between high and low til subgroups, at 25% and 29%, respectively

* Continues to monitor all patients enrolled in study for a 2-year duration Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below